Pholcodine

Mechanism of action

Pholcodine is readily absorbed from the gastrointestinal tract and freely crosses the blood–brain barrier. It acts primarily on the central nervous system (CNS), causing depression of the cough reflex, partly by a direct effect on the cough centre in the medulla. It is metabolized in the liver and its action may be prolonged in individuals with hepatic insufficiency (i.e. liver problems). Its use is therefore contraindicated in patients with liver disease, while care is advised in patients with hepatic impairment.

Metabolism and excretion

Pholcodine is slowly biotransformed in the body via oxidation and conjugation to a series of metabolites that are eliminated primarily in the urine. With an average half-life of approximately 2.3 days, steady-state in someone taking the drug chronically would not be reached for nearly 2 weeks. Nearly one-half of a single dose is eventually excreted as free or conjugated parent drug. The most important urinary metabolite is conjugated morphine, which may be detectable for days or weeks after the last dose. This could trigger a positive result for opiates in a urine drug testing program.

Side effects

Side effects are rare and may include dizziness and gastrointestinal disturbances such as nausea or vomiting. Adverse effects such as constipation, drowsiness, excitation, ataxia and respiratory depression have been reported occasionally or after large doses. The primary safety concerns with pholcodine revolve around death during general anaesthesia.

Anaphylaxis during general anaesthesia

Administration of pholcodine causes production of antibodies linked with fatalities during surgery, when essential neuromuscular blocking agents (NMBAs) are administered to prevent patient movement under general anaesthesia. These antibody levels gradually fall to low levels several years after last dose of pholcodine. However, the presence of these antibodies causes a 300-fold increase in risk of anaphylaxis during anaesthesia.

The link was suspected when neighbouring Norway and Sweden were found to have tenfold differences of surgical anaphylaxis deaths. Sweden had no products approved containing pholcodine, whereas 40% of the population in Norway had consumed the single approved pholcodine product. A corresponding fall in anaesthesia deaths followed.

A similar disparity exists between NMBA anaphylaxis rates in Australia, where pholcodine consumption is high and the US, where pholcodine is banned. In the US, anaphylaxis rates are so low that some anaesthetists question the existence of such reactions to NMBAs. Conversely, Australian anaesthetists have requested a ban on pholcodine due to the high anaphylaxis rate in the country. However, the Therapeutic Goods Administration declined the request in January 2015, pending further reviews to follow. In February 2023, the Therapeutic Goods Administration reversed its previous decision and banned products containing pholcodine.

In contrast, the European Medicines Agency's 2012 "Assessment report for Pholcodine containing medicinal products" concludes this: The Committee considered that evidence of an association between pholcodine use and development of NMBA-related anaphylaxis is circumstantial, not entirely consistent and therefore does not support the conclusion that there is a significant risk of cross-sensitisation to NMBAs and subsequent development of anaphylaxis during surgery.

In September 2022, the European Medicines Agency (EMA) started reviewing its position at the request of the French ANSM, which withdrew all pholcodine-containing medicines after preliminary results from a local study showed an increased risk of anaphylaxis after pholcodine use. The EMA review concluded on 14 December 2022 with the recommendation that pholcodine be withdrawn from the EU market. This decision was ratified by the European Commission in March 2023. The UK government recalled all products containing pholcodine in March 2023.

References

References

1. Anvisa. (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. "Potter's Pholcodine cough pastilles". Lloyds Pharmacy.
3. (2007). "British National Formulary 54". BMJ Publishing Group Ltd., RPS Publishing.
4. (11 June 2009). "Legislation - Controlled Substances". U.S. [[Food and Drug Administration]] (FDA).
5. (23 March 2023). "Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure".
6. (2 December 2022). "EMA recommends withdrawal of pholcodine medicines from EU market".
7. (28 February 2023). "Pholcodine".
8. (1 March 2023). "About pholcodine cough medicines cancelled by the TGA and recalled from pharmacies for safety reasons".
9. (December 1990). "Toxicological detection of pholcodine and its metabolites in urine and hair using radio immunoassay, fluorescence polarisation immunoassay, enzyme immunoassay, and gas chromatography-mass spectrometry". International Journal of Legal Medicine.
10. (2008). "Disposition of Toxic Drugs and Chemicals in Man". Biomedical Publications.
11. (17 January 2015). "Anaesthetists campaign for pholcodine cough medicines to become prescription-only products". Royal Pharmaceutical Society.
12. (August 2009). "The pholcodine story". Immunology and Allergy Clinics of North America.
13. (July 2012). "The Pholcodine Case. Cough Medicines, IgE-Sensitization, and Anaphylaxis: A Devious Connection". The World Allergy Organization Journal.
14. (July 2011). "IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market". Allergy.
15. (June 2013). "Anaphylaxis to neuromuscular blocking drugs: incidence and cross-reactivity in Western Australia from 2002 to 2011". British Journal of Anaesthesia.
16. (April 2004). "Anaphylactic reactions to neuromuscular blocking drugs: are we making the correct diagnosis?". Anesthesia and Analgesia.
17. (2014). "Anaphylaxis and anaesthesia–can treating a cough kill?". Australian Prescriber.
18. (April 2014). "Pholcodine consumption and immunoglobulin E-sensitization in atopics from Australia, Korea, and Japan". Asia Pacific Allergy.
19. Medew, Julia. (5 January 2015). "Cough medicine alert over surgery". The Age.
20. "Pholcodine cough medicines cancelled by the TGA and recalled from pharmacies for safety reasons".
21. (17 February 2012). "Assessment report for Pholcodine containing medicinal products". European Medicines Agency.
22. (9 February 2022). "Review of pholcodine medicines started". European Medicines Agency.
23. "Pholcodine: Suspension des autorisations de mise sur le marché et retrait de toutes les boîtes de sirop contenant de la pholcodine en raison d'un risque d'allergie croisée avec les curares". Agence nationale de sécurité du médicament et des produits de santé (ANSM).
24. (August 2022). "Rationale for the Triggering of Procedure Under Article 107i of Directive 2001/83/EE on Pholcodine". French Competent Authority (ANSM - French National Agency for Medicines and Health Products Safety) Agence nationale de sécurité du médicament et des produits de santé.
25. (1 December 2022). "EMA recommends withdrawal of pholcodine medicines from EU market". European Medicines Agency.
26. (6 March 2023). "Pholcodine medicines withdrawn from EU market". European Medicines Agency.
27. Medicines and Healthcare products Regulatory Agency. (14 March 2023). "Class 2 Medicines Recall: Various Marketing Authorisation Holders, pholcodine-containing products, EL (23)A/09".